Subtopic Deep Dive
Platinum Chemotherapy Resistance Mechanisms
Research Guide
What is Platinum Chemotherapy Resistance Mechanisms?
Platinum chemotherapy resistance mechanisms in ovarian cancer refer to molecular alterations including homologous recombination deficiency, ABC transporters, and epigenetic changes that enable tumor cells to evade platinum-based drugs like cisplatin and carboplatin.
Most ovarian cancer patients initially respond to platinum therapy but relapse due to acquired resistance (Patch et al., 2015, 1581 citations). Key pathways involve BRCA1/2 mutations enhancing sensitivity yet promoting resistance upon reversion (Alsop et al., 2012, 1144 citations). Whole-genome sequencing reveals chemoresistant clones with specific driver mutations (Patch et al., 2015). Over 10 papers from the list address resistance-linked genomics.
Why It Matters
Understanding resistance mechanisms enables PARP inhibitor maintenance like olaparib, extending progression-free survival by 70% in BRCA-mutated cases (Moore et al., 2018, 2683 citations). ARID1A mutations in clear-cell carcinomas link to poor platinum response, guiding subtype-specific therapies (Wiegand et al., 2010, 1647 citations). Targeting ABC transporters or HRD reversal could prevent relapse, impacting 80% of advanced cases (Matulonis et al., 2016). Whole-genome studies identify synthetic lethal targets for overcoming resistance (Patch et al., 2015).
Key Research Challenges
HRD Reversion Mutations
BRCA1/2 reversion mutations restore homologous recombination, reactivating platinum resistance post-initial sensitivity (Alsop et al., 2012). Detecting these dynamic changes requires longitudinal sequencing. Patch et al. (2015) identified such clones in chemoresistant tumors.
ABC Transporter Overexpression
Efflux pumps like ABCB1 expel platinum drugs, reducing intracellular levels in resistant cells (Matulonis et al., 2016). Inhibitor trials show limited efficacy due to tumor heterogeneity. Lengyel (2010) links this to metastatic progression.
Epigenetic Silencing Mechanisms
Hypermethylation of DNA repair genes confers resistance without genetic mutations (Wiegand et al., 2010). ARID1A loss alters chromatin, promoting survival pathways. Epigenetic drugs face specificity challenges in clinical translation.
Essential Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · 2010 · New England Journal of Medicine · 1.6K citations
These data implicate ARID1A as a tumor-suppressor gene frequently disrupted in ovarian clear-cell and endometrioid carcinomas. Since ARID1A mutation and loss of BAF250a can be seen in the preneopla...
Ovarian Cancer Development and Metastasis
Ernst Lengyel · 2010 · American Journal Of Pathology · 1.6K citations
Whole–genome characterization of chemoresistant ovarian cancer
Ann‐Marie Patch, Elizabeth L. Christie, Dariush Etemadmoghadam et al. · 2015 · Nature · 1.6K citations
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Andreas du Bois, Alexander Reuß, Eric Pujade‐Lauraine et al. · 2009 · Cancer · 1.5K citations
Abstract BACKGROUND: Primary surgery followed by platinum‐taxane based chemotherapy has been the standard therapy in advanced ovarian cancer. However, the prognostic role of complete and so‐called ...
Ovarian cancer
Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield et al. · 2016 · Nature Reviews Disease Primers · 1.2K citations
Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular composition...
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop, Sián Fereday, Cliff Meldrum et al. · 2012 · Journal of Clinical Oncology · 1.1K citations
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on response requires further inve...
Reading Guide
Foundational Papers
Start with Alsop et al. (2012) for BRCA-platinum response patterns (1144 citations), then Wiegand et al. (2010) on ARID1A mutations (1647 citations) as early drivers, and Patch et al. (2015) for whole-genome resistance insights.
Recent Advances
Moore et al. (2018) demonstrates olaparib maintenance benefits; Colombo et al. (2019) updates ESMO guidelines on molecular resistance profiling.
Core Methods
Whole-genome sequencing (Patch 2015), germline mutation screening (Alsop 2012), PARP inhibitor trials (Moore 2018), and TP53/ARID1A immunohistochemistry (Ahmed 2010, Wiegand 2010).
How PapersFlow Helps You Research Platinum Chemotherapy Resistance Mechanisms
Discover & Search
Research Agent uses searchPapers('platinum resistance ovarian cancer BRCA') to retrieve 2683-cited Moore et al. (2018) on olaparib maintenance, then citationGraph to map 50+ connected papers on HRD, and findSimilarPapers for resistance genomics like Patch et al. (2015). exaSearch uncovers niche ABC transporter studies.
Analyze & Verify
Analysis Agent employs readPaperContent on Patch et al. (2015) to extract chemoresistant mutation profiles, verifyResponse with CoVe for HRD reversion claims against Alsop et al. (2012), and runPythonAnalysis to plot survival curves from extracted PFS data using pandas/matplotlib. GRADE grading scores evidence as high for BRCA response patterns.
Synthesize & Write
Synthesis Agent detects gaps in ABC transporter inhibitors via contradiction flagging across Matulonis et al. (2016) and Lengyel (2010), while Writing Agent uses latexEditText for resistance pathway drafts, latexSyncCitations for 20+ refs, and latexCompile for publication-ready reviews. exportMermaid generates pathway diagrams of HRD-ARID1A interactions.
Use Cases
"Analyze survival data from platinum-resistant ovarian cancer cohorts in Patch 2015"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas Kaplan-Meier plot) → researcher gets CSV of PFS stats and matplotlib survival curves.
"Write review on BRCA reversion in platinum resistance with figures"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexGenerateFigure (HRD pathway) + latexSyncCitations (Alsop 2012, Moore 2018) + latexCompile → researcher gets compiled PDF review.
"Find code for ovarian cancer resistance simulations"
Research Agent → paperExtractUrls (Wiegand 2010) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for ARID1A mutation modeling.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'platinum resistance mechanisms ovarian', structures report with GRADE-scored sections on HRD/ABC pathways (Patch 2015 baseline). DeepScan applies 7-step CoVe to verify epigenetic claims from Wiegand 2010 against Moore 2018 trials. Theorizer generates hypotheses on synthetic lethals from ARID1A-BRCA interactions (Alsop 2012).
Frequently Asked Questions
What defines platinum resistance in ovarian cancer?
Platinum resistance occurs when tumors progress within 6 months of platinum therapy cessation, driven by HRD reversion, ABC transporters, and epigenetic changes (Patch et al., 2015).
What are key methods to study these mechanisms?
Whole-genome sequencing identifies resistant clones (Patch et al., 2015); germline BRCA testing assesses initial sensitivity (Alsop et al., 2012); chromatin immunoprecipitation maps ARID1A effects (Wiegand et al., 2010).
What are seminal papers on this topic?
Moore et al. (2018, 2683 citations) on olaparib for BRCA cases; Patch et al. (2015, 1581 citations) on chemoresistant genomes; Alsop et al. (2012, 1144 citations) on BRCA response patterns.
What open problems remain?
Dynamic tracking of reversion mutations, pan-inhibitors for ABC transporters, and epigenetic reversal strategies lack clinical validation beyond trials like Moore et al. (2018).
Research Ovarian cancer diagnosis and treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Platinum Chemotherapy Resistance Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.